Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.

@article{Colnot2000PhaseIT,
  title={Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.},
  author={David R. Colnot and Jasper Quak and J. D. Roos and Arthur van Lingen and Abraham J. Wilhelm and Gerard J van Kamp and Peter C. Huijgens and Gordon B J Snow and Guus A. M. S. van Dongen},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2000},
  volume={41 12},
  pages={1999-2010}
}
UNLABELLED A phase I therapy study was conducted to determine the safety, maximum tolerated dose (MTD), pharmacokinetics, dosimetry, immunogenicity, and therapeutic potential of 186Re-labeled anti-CD44v6 chimeric monoclonal antibody (cMAb) U36 in patients with squamous cell carcinoma of the head and neck (HNSCC). The potential of a diagnostic study with 99mTc-cMAb U36 to predict the biodistribution of 186Re-cMAb U36 was evaluated. METHODS Thirteen patients with recurrent or metastatic HNSCC… CONTINUE READING